Status:
COMPLETED
Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
The Korean Urological Association
GlaxoSmithKline
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
MALE
50+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether dutasteride may influence the expression of angiogenesis factors such as hypoxia inducible factor (HIF)-1alpha and vascular endothelial growth factor ...
Detailed Description
A total of 41 patients awaiting transurethral resection of the prostate (TURP) will be divided into two groups (1:1); twenty patients will receive no medication and 21 will receive 0.5 mg dutasteride ...
Eligibility Criteria
Inclusion
- informed consent
- 50 years old or older
- International Prostate Symptom Score (IPSS) \>8
- Maximum flow rate (Qmax) \<15 ml/s
- transurethral resection of the prostate (TURP)
Exclusion
- urethral catheter
- urinary tract infection (UTI)
- liver disease
- renal disease
- unexplained hematuria
- prostate specific antigen (PSA) \> 4ng/ml (included if prostate biopsy was negative)
- interstitial cystitis
- bladder cancer or prostate cancer
- pelvic surgery or irradiation
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00880672
Start Date
January 1 2008
End Date
April 1 2009
Last Update
June 12 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.